Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 55

Sort by

Sort Order Select

Journal Articles

Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

Naseema Gangat, Rimal Ilyas, Kristen McCullough, Kebede H. Begna, Aref Al-Kali, Mrinal M.M. Patnaik, Mark R. Litzow, William J. Hogan, Abhishek A. Mangaonkar, Hassan B. Alkhateeb, Mithun V. Shah, Michelle A Elliott, James M. Foran, Talha Badar, Jeanne M. Palmer, Curtis A. Hanson, Animesh Pardanani, Ayalew Tefferi

Blood (2022) 140 (Supplement 1): 9675–9676.

https://doi.org/10.1182/blood-2022-163485

Published: 2022

Journal Articles

Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

Farah Fleti, Amritpal Singh, Aref Al-Kali, James M. Foran, Michelle A Elliott, Kebede Begna, Talha Badar, Nandita Khera, Mithun V. Shah, Hassan B. Alkhateeb, Maymona Abdelmagid, Kaaren K. Reichard, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2022) 140 (Supplement 1): 6940–6941.

https://doi.org/10.1182/blood-2022-163518

Published: 2022

Journal Articles

Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021

Maymona Abdelmagid, Aref Al-Kali, Kebede H. Begna, William J. Hogan, Mark R. Litzow, Abhishek A. Mangaonkar, Mrinal M.M. Patnaik, Michelle A Elliott, Hassan B. Alkhateeb, Min Shi, Matthew Howard, Kaaren K. Reichard, Rhett P. Ketterling, Animesh Pardanani, Naseema Gangat, Ayalew Tefferi

Blood (2022) 140 (Supplement 1): 9735–9736.

https://doi.org/10.1182/blood-2022-163450

Published: 2022

Journal Articles

Bortezomib and/or Daratumumab for Treatment of Refractory Autoimmune Hemolytic Anemia

John McGlothlin, Jithma P. Abeykoon, Eyad Al-Hattab, Aneel A. Ashrani, Michelle A Elliott, Ronald Go, C. Christopher Hook, Animesh Pardanani, Rajiv K. Pruthi, Meera Sridharan, Alexandra P. Wolanskyj

Blood (2022) 140 (Supplement 1): 5328–5330.

https://doi.org/10.1182/blood-2022-159270

Published: 2022

Journal Articles

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias of Undetermined Significance

Zhuoer Xie, Kristen McCullough, Terra Lasho, Jenna A. Fernandez, Christy Finke, Michelle Renee Amundson, Betsy Laplant, Abhishek A. Mangaonkar, Naseema Gangat, Kaaren K. Reichard, Michelle A Elliott, Thomas E. Witzig, Mrinal M.M. Patnaik

Blood (2022) 140 (Supplement 1): 2893–2894.

https://doi.org/10.1182/blood-2022-165163

Published: 2022

Journal Articles

Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome

Animesh Pardanani, Ayalew Tefferi, Amritpal Singh, Aref Al-Kali, Mrinal M. Patnaik, William J. Hogan, Kebede Begna, Michelle A Elliott, Nandita Khera, Jeanne M. Palmer, Naseema Gangat, Attilio Orazi, Katalin Kelemen, Kaaren K. Reichard, Dong Chen

Blood (2022) 140 (Supplement 1): 6872–6873.

https://doi.org/10.1182/blood-2022-167720

Published: 2022

Journal Articles

Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases

Ayalew Tefferi, Jaya Kittur, Faiqa Farrukh, Kebede H. Begna, Mrinal M. Patnaik, Aref Al-Kali, Michelle A Elliott, Kaaren K. Reichard, Naseema Gangat, Animesh D. Pardanani

Blood (2021) 138 (Supplement 1): 3657.

https://doi.org/10.1182/blood-2021-151009

Published: 2021

Journal Articles

Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN)

Mithun V. Shah, Abhishek A. Mangaonkar, Kebede H. Begna, Hassan B. Alkhateeb, Patricia Greipp, Dong Chen, David S. Viswanatha, Rong He, Michelle A Elliott, William J Hogan, Mark R. Litzow, Kristen McCullough, Ayalew Tefferi, Naseema Gangat, Mrinal M. Patnaik, Aref Al-Kali

Blood (2021) 138 (Supplement 1): 1096.

https://doi.org/10.1182/blood-2021-145696

Published: 2021

Journal Articles

Efficacy of Venetoclax Plus Hypomethylating Agent in Blast Phase Myeloproliferative Neoplasm

Erika Morsia, MD, Naseema Gangat, MBBS, James M. Foran, MD, Jeanne M. Palmer, MD, Michelle A Elliott, MD, Ayalew Tefferi, MD

Blood (2020) 136 (Supplement 1): 21.

https://doi.org/10.1182/blood-2020-134701

Published: 2020

Journal Articles

A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015

Gordon Ruan, MD, Caleb J. Smith, MD, Courtney Day, William Harmsen, Abhishek A. Mangaonkar, MBBS, Hassan B. Alkhateeb, MD, Kebede H. Begna, MD, Aref Al-Kali, MD, Mark Litzow, MD, William J Hogan, MB, BCh, Naseema Gangat, MBBS, Animesh Pardanani, MBBS, PhD, Michelle A Elliott, MD, Ayalew Tefferi, MD, Ronald S. Go, MD, Mrinal M. Patnaik, MDMBBS, Mithun Vinod Shah, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136350

Published: 2020

Journal Articles

Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures

Blood (2019) 134 (Supplement_1): 1710.

https://doi.org/10.1182/blood-2019-123877

Published: 2019

Journal Articles

Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3 -ITD: Results from an International Collaboration

Sabine Kayser, MD, Michelle A Elliott, MD, Marlise Luskin, MDMS, Andrew M. Brunner, MD, Michael Kramer, M.Sc., Zdenek Racil, MD, Zuzana Sustkova, MD, Petr Cetkovsky, MD MBA, PhD, Jan Novak, MD PhD, Friedrich Stoelzel, MD, Christian Thiede, MD, Carsten Müller-Tidow, MD, Uwe Platzbecker, Christoph Röllig, MD MSC, Richard F. Schlenk, MD, Mark J. Levis, MD

Blood (2019) 134 (Supplement_1): 2693.

https://doi.org/10.1182/blood-2019-125317

Published: 2019

Journal Articles

Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial

Meera Yogarajah, MD, William J Hogan, MB, BCh, Naseema Gangat, MBBS, Dong Chen, MD PhD, Rong He, MD, Hassan B. Alkhateeb, MD, Mithun Vinod Shah, MD PhD, Mrinal M Patnaik, MDMBBS, Michelle A Elliott, MD, Mark Litzow, MD, Aref Al-Kali, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Kebede H. Begna, MD

Blood (2019) 134 (Supplement_1): 3863.

https://doi.org/10.1182/blood-2019-125361

Published: 2019

Journal Articles

Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB)

Meera Yogarajah, MD, Phuong L. Nguyen, MD, Rong He, MD, Hassan B. Alkhateeb, MD, Mithun Vinod Shah, MD PhD, Mrinal M Patnaik, MDMBBS, Kebede H. Begna, MD, Michelle A Elliott, MD, Naseema Gangat, MBBS, William J Hogan, MB, BCh, Ayalew Tefferi, MD, Mark Litzow, MD, Aref Al-Kali, MD

Blood (2019) 134 (Supplement_1): 5441.

https://doi.org/10.1182/blood-2019-125439

Published: 2019

Journal Articles

Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)

Guadalupe Belen Antelo, MD, Giacomo Coltro, MD, Abhishek A Mangaonkar, MBBS, Terra Lasho, PhD, Christy Finke, BS, Ryan M. Carr, MD PhD, Naseema Gangat, MBBS, Moritz Binder, MDMPH, Aref Al-Kali, MD, Michelle A Elliott, MD, Matthew T Howard, MD, Rebecca L. King, MD, William J Hogan, MB, BCh, Mark Litzow, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Martin Fernandez-Zapico, MD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 4182.

https://doi.org/10.1182/blood-2019-126199

Published: 2019

Journal Articles

Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes

Kalyan Nadiminti, Abhishek A Mangaonkar, MBBS, Kimberly J. Langer, D.N.P., C.N.P., Shakila P Khan, MD, Vilmarie Rodriguez, MD, Naseema Gangat, MBBS, Michelle A Elliott, MD, Hassan B. Alkhateeb, MD, Mithun Vinod Shah, MD PhD, Mark Litzow, MD, William J Hogan, MB, BCh, Saad S. Kenderian, MD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 3300.

https://doi.org/10.1182/blood-2019-121742

Published: 2019

Journal Articles

3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

Natasha Szuber, MD, Mythri Mudireddy, MBBS, Maura Nicolosi, MD, Domenico Penna, MD, Rangit Vallapureddy, MBBS, Terra L. Lasho, PhD, Christy Finke, BS, Kebede H. Begna, MD, Michelle A. Elliott, MD, C. Christopher Hook, MD, Alexandra Wolanskyj, MD, Mrinal M. Patnaik, MD MBBS, Curtis A. Hanson, MD, Rhett P. Ketterling, Shireen Sirhan, MD, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Lambert Busque, MD, Ayalew Tefferi, MD

Blood (2018) 132 (Supplement 1): 3035.

https://doi.org/10.1182/blood-2018-99-109740

Published: 2018

Journal Articles

The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia

Blood (2018) 132 (Supplement 1): 5440.

https://doi.org/10.1182/blood-2018-99-118600

Published: 2018

Journal Articles

Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide

Ayalew Tefferi, MD, Natasha Szuber, MD, Kebede H. Begna, MD, Mrinal M. Patnaik, MD MBBS, Michelle A. Elliott, MD, C. Christopher Hook, MD, Alexandra Wolanskyj, MD, Curtis A. Hanson, MD, Rhett P. Ketterling, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS

Blood (2018) 132 (Supplement 1): 4287.

https://doi.org/10.1182/blood-2018-99-116601

Published: 2018

Journal Articles

Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia

Blood (2018) 132 (Supplement 1): 4344.

https://doi.org/10.1182/blood-2018-99-113881

Published: 2018

NARROW

Predictors of Response to Venetoclax Plus Hypomethylating Agent Therapy and Survival in Blast-Phase Myeloproliferative Neoplasm

Therapy-Related Myelodysplastic Syndromes with Isolated Del(5q): Comparative Analysis of Phenotype and Long-Term Survival

Leukemic Transformation of Myeloproliferative Neoplasms in the Post-Ruxolitinib Era: Analysis of 103 Consecutive Cases Diagnosed 2011-2021

Bortezomib and/or Daratumumab for Treatment of Refractory Autoimmune Hemolytic Anemia

Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias of Undetermined Significance

Reappraisal of Mast Cell Leukemia Based on a Single Institution Review of 16 Cases: Role of Mast Cell Morphology in Determining Clinical Outcome

Cladribine Therapy for Advanced and Indolent Systemic Mastocytosis: Mayo Clinic Experience in 42 Consecutive Cases

Therapy-Related Cytopenia of Undetermined Significance (t-CCUS) As a Precursor to Therapy-Related Myeloid Neoplasms (t-MN)

Efficacy of Venetoclax Plus Hypomethylating Agent in Blast Phase Myeloproliferative Neoplasm

A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015

Clinical Categorization of Chronic Myelomonocytic Leukemia into Proliferative and Dysplastic Subtypes Correlates with Distinct Genomic, Transcriptomic and Epigenomic Signatures

Characteristics and Outcome of Patients with Core Binding Factor Acute Myeloid Leukemia and FLT3 -ITD: Results from an International Collaboration

Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial

Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB)

Response to Erythropoiesis Stimulating Agents in Patients with WHO-Defined Myelodysplastic Syndrome/Myeloproliferative Neoplasm with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)

Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes

3,023 Mayo Clinic Patients with Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups

The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia

Decreased Survival and Increased Rate of Fibrotic Progression in Essential Thrombocythemia Chronicled after the FDA Approval Date of Anagrelide

Indoleamine 2,3-Dioxygenase-1 Expressing Dendritic Cell Populations Are Associated with Tumor-Induced Immune Tolerance & Aggressive Disease Biology in Chronic Myelomonocytic Leukemia

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only